Phenolic complex k110-42
Drug900 mg/kg once oral in form of sachet for 6 month
NCT Number: NCT07284693
The goal of this study is to evaluate the efficacy of phenolic complex k110-42 on cognitive function of children with Down syndrome
Trial opening soon.
Get Notified4 year–8 year
All sexes
Interventional
Phase 3
Children with Down syndrome (DS) often face a variety of cognitive and developmental challenges. These challenges may include delays in speech, motor skills, and social-emotional development. Among these, difficulties with attention and focus are particularly prominent, making it harder for children with DS to participate in academic and everyday activities.
One promising avenue for improving cognitive function is the use of natural compounds with neuroprotective and cognitive-enhancing properties. The phenolic complex K110-42 (Neumentix), derived from the extract of spearmint, has garnered attention for its potential benefits in cognitive performance.
Specifically, polyphenols contained within the aqueous extracts from the Lamiaceae family could mechanistically account for the reported benefits on cognitive performance. Polyphenols found in aqueous extracts of spearmint such as salvianolic and rosmarinic acids have been shown to have anti-oxidant, anti-inflammatory, anti-acetylcholinesterase, and neuroprotective biological activity both in vitro and in vivo .
Phenolic offers a number of benefits on cognitive functions and it is plausible that its anti-inflammatory, antioxidant, anti-fibrotic effects, enhance attention, improving vascular endothelial functions and enhancement of metabolic performances. Because of the multiple functions, phenolic has direct effects on attention deficit in DS.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
900 mg/kg once oral in form of sachet for 6 month
0 mg/kg once sachet oral for 6 month
Time frame: At baseline before any intervention, at 3 month ,at 6 month
Cognitive assessment will be assessed using Conners' Kiddie Continuous Performance Test (K-CPT).
Time frame: At baseline before any intervention , at 3 month , at 6 month
Contact information is provided by the study sponsor or research team.
Mansoura University
Other
Clinical Study Evaluating the Efficacy of Phenolic Complex k110-42 Therapy on Cognitive Functions of Children With Down Syndrome
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07343154
Brain Diseases, Central Nervous System Diseases
View Trial DetailsNCT06708026
Behavior, Behavioral Symptoms
Hong Kong
View Trial DetailsNCT07637357
Bariatric Sleeve Gastrectomy, Cognition Disorders
Istanbul, Sancaktepe, Turkey (Türkiye)
View Trial DetailsNCT07194590
Blood Pressure, Cerebrovascular Function
Aurora, Colorado, United States
View Trial Details